Abstract:
Objective To explore the relationship between cancer pain and algogenic substances and immune function to screen out sensitive indicators for cancer-pain assessment and curative-effect monitoring, as well as to preliminary explore the role of algogenic substances in cancer pain. Methods A total of 60 patients with cancer pain diagnosed at the Yunnan Cancer Hospital from January 2016 to January 2019 were selected as the test group, and 30 healthy people and 30 patients with painless tumours were selected as the control group. Enzyme-linked immunosorbent assay was used to determine the levels of TNF-α, IL-6, β-endorphin, NGF, and LPA in plasma. Flow cytometry was used to detect the change in peripheral blood T lymphocyte subsets before and after cancer-pain control. The relationship of the expression of algogenic substances with the degree of cancer pain, outbreak pain, and distant metastasis was analysed statistically. Results The contents of TNF-α, IL-6, β-endorphin, NGF, and LPA in the experimental group were significantly higher than those in the control group. The levels of TNF-α, IL-6, β-endorphin, and NGF in serum after cancer-pain control were (87.77±11.60) ng/L, (33.33±6.43) ng/mL, (24.00±5.93) ng/mL, and (19.85±3.78) pg/mL, respectively. It was significantly lower than the level before cancer-pain control [(220.20±32.11) ng/L, (59.48±10.26) ng/mL, (38.62±8.01) ng/mL, (34.32±6.21) pg/mL], but no significant difference existed in LPA expression before and after cancer-pain control. The contents of TNF-α, IL-6, NGF, and LPA were related to the degree of cancer pain, outbreak pain, and distant metastasis. The expression level of β-endorphin was related to the degree of cancer pain and distant metastasis. The percentages of CD3+, CD4+, and CD4+/CD8+ after cancer pain control were significantly higher than those before cancer-pain control, but the percentage of CD8+ after cancer pain control was significantly lower than before cancer pain control, and the difference was statistically significant. Conclusion TNF-α, IL-6, β-endorphin, NGF, and LPA may play certain roles in cancer pain, which can be used to evaluate cancer pain and monitor therapeutic effect. Cancer pain can reduce the body's immune function.